Blair William & Co. IL continued to hold its stake in shares of Omeros Corporation (NASDAQ:OMER) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 11,000 shares of the biopharmaceutical company’s stock at the end of the second quarter. Blair William & Co. IL’s holdings in Omeros Corporation were worth $116,000 as of its most recent filing with the SEC.

A number of other hedge funds have also modified their holdings of the stock. Sheaff Brock Investment Advisors LLC acquired a new stake in shares of Omeros Corporation during the second quarter valued at about $105,000. Bourgeon Capital Management LLC acquired a new stake in shares of Omeros Corporation during the second quarter valued at about $158,000. BlackRock Group LTD increased its stake in shares of Omeros Corporation by 64.4% in the first quarter. BlackRock Group LTD now owns 12,080 shares of the biopharmaceutical company’s stock valued at $186,000 after buying an additional 4,734 shares during the period. Mesirow Financial Investment Management Equity Management acquired a new stake in shares of Omeros Corporation during the second quarter valued at about $244,000. Finally, State Board of Administration of Florida Retirement System increased its stake in shares of Omeros Corporation by 1.2% in the second quarter. State Board of Administration of Florida Retirement System now owns 30,737 shares of the biopharmaceutical company’s stock valued at $323,000 after buying an additional 351 shares during the period. 47.99% of the stock is currently owned by institutional investors.

Shares of Omeros Corporation (NASDAQ:OMER) traded up 3.30% during trading on Thursday, hitting $11.89. The stock had a trading volume of 163,481 shares. The firm’s 50-day moving average is $11.42 and its 200 day moving average is $12.29. Omeros Corporation has a 52-week low of $8.90 and a 52-week high of $16.80. The firm’s market cap is $467.19 million.

Omeros Corporation (NASDAQ:OMER) last released its quarterly earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.18. The business earned $10 million during the quarter, compared to analyst estimates of $9.80 million. The business’s revenue for the quarter was up 212.5% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.44) EPS. On average, analysts expect that Omeros Corporation will post ($1.55) EPS for the current year.

Several research firms have weighed in on OMER. Cantor Fitzgerald restated a “buy” rating and set a $21.00 price target on shares of Omeros Corporation in a report on Wednesday, August 10th. Maxim Group cut their price target on Omeros Corporation from $30.00 to $19.00 and set a “buy” rating for the company in a report on Wednesday, August 10th. WBB Securities restated a “buy” rating and set a $75.00 price target on shares of Omeros Corporation in a report on Tuesday, June 14th. Wedbush restated an “outperform” rating and set a $56.00 price target (down previously from $62.00) on shares of Omeros Corporation in a report on Thursday, August 11th. Finally, FBR & Co restated an “outperform” rating and set a $38.00 price target on shares of Omeros Corporation in a report on Wednesday, June 29th. One research analyst has rated the stock with a sell rating and six have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $35.86.

In related news, VP Marcia S. Kelbon sold 16,000 shares of the company’s stock in a transaction dated Thursday, September 15th. The stock was sold at an average price of $10.91, for a total value of $174,560.00. Following the completion of the transaction, the vice president now owns 179,597 shares of the company’s stock, valued at approximately $1,959,403.27. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Marcia S. Kelbon sold 15,900 shares of the company’s stock in a transaction dated Monday, August 15th. The stock was sold at an average price of $11.56, for a total value of $183,804.00. Following the completion of the transaction, the vice president now directly owns 179,497 shares of the company’s stock, valued at approximately $2,074,985.32. The disclosure for this sale can be found here. 13.60% of the stock is owned by corporate insiders.

About Omeros Corporation

Omeros Corporation is a biopharmaceutical company engaged in discovering, developing and commercializing small-molecule and protein therapeutics for market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. The Company’s marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens replacement.

5 Day Chart for NASDAQ:OMER

Want to see what other hedge funds are holding OMER? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omeros Corporation (NASDAQ:OMER).

Receive News & Ratings for Omeros Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros Corporation and related companies with MarketBeat.com's FREE daily email newsletter.